Logotype for Cue Biopharma Inc

Cue Biopharma (CUE) investor relations material

Cue Biopharma Cantor Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cue Biopharma Inc
Cantor Global Healthcare Conference 2025 summary5 Sep, 2025

Key product and clinical program updates

  • Lead dual agonist VK2735 is in two phase 3 trials (VANQUISH 1 and 2) for obesity, with strong enrollment and operational progress reported.

  • Recent phase 2 oral formulation study showed clear dose response and good efficacy, but high-dose arms had notable adverse events, leading to focus on lower, better-tolerated doses for future studies.

  • Maintenance market is seen as a major opportunity, with plans for monthly and low-dose oral formulations to support long-term weight loss.

  • Amylin analog program is advancing, with a pre-IND meeting scheduled and potential for both combination and monotherapy approaches.

Clinical development strategy and regulatory plans

  • Full phase 2 oral data expected soon; end-of-phase 2 FDA meeting planned to determine next steps, with possible phase 3 initiation in the first half of next year.

  • Dose selection for future studies will likely focus on 20–80 mg range, with titration and tablet size/count optimization to improve tolerability and retention.

  • Discontinuation rates in obesity trials are a concern; strategies include offering placebo patients active drug in extension and careful patient selection.

  • Subcutaneous phase 3 trials are progressing well, with high investigator and patient engagement.

Commercialization and market outlook

  • Company has doubled in size to support clinical operations, with further growth expected over the next 18–24 months.

  • Commercial strategy may blend a smaller sales force with a strong online direct-to-patient presence, reflecting evolving obesity market dynamics.

  • Cash-pay obesity market is expected to remain significant, with flexibility in pricing and access models.

  • Maintenance therapy and seamless transition between subcutaneous and oral formulations are seen as key differentiators.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cue Biopharma earnings date

Logotype for Cue Biopharma Inc
Q3 202512 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cue Biopharma earnings date

Logotype for Cue Biopharma Inc
Q3 202512 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. The company is focused on developing its proprietary platform designed to modulate immune signaling with cytokine infiltration and inflammatory mediators to generate personalized therapeutic immunotherapies.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage